Certara (NASDAQ:CERT) Sets New 12-Month Low – Here’s Why

Certara, Inc. (NASDAQ:CERT)’s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $8.12 and last traded at $8.1540, with a volume of 1207198 shares trading hands. The stock had previously closed at $8.33.

Analyst Upgrades and Downgrades

Several research firms recently commented on CERT. Wall Street Zen downgraded shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a report on Thursday, November 13th. UBS Group dropped their price target on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Zacks Research raised Certara from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Finally, Craig Hallum initiated coverage on Certara in a research note on Monday, September 29th. They set a “buy” rating and a $16.00 price objective on the stock. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $14.67.

Certara Stock Up 2.0%

The firm has a 50 day simple moving average of $11.45 and a two-hundred day simple moving average of $11.21. The stock has a market capitalization of $1.32 billion, a P/E ratio of 118.43 and a beta of 1.44. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. Certara had a return on equity of 5.18% and a net margin of 2.62%.The company had revenue of $104.62 million during the quarter, compared to analysts’ expectations of $104.53 million. During the same quarter in the previous year, the firm earned $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, equities research analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Insider Activity

In related news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total transaction of $559,366.08. Following the sale, the insider directly owned 73,979 shares of the company’s stock, valued at approximately $807,850.68. The trade was a 40.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 2.33% of the company’s stock.

Institutional Trading of Certara

A number of hedge funds and other institutional investors have recently modified their holdings of CERT. AdvisorNet Financial Inc acquired a new position in Certara in the 2nd quarter worth about $25,000. First Horizon Corp bought a new stake in Certara during the 3rd quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd bought a new stake in Certara during the 1st quarter worth approximately $31,000. Versant Capital Management Inc increased its position in Certara by 66.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after acquiring an additional 1,153 shares during the period. Finally, AlphaQuest LLC bought a new position in shares of Certara during the first quarter valued at $39,000. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.